These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34015579)

  • 21. Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.
    Zhang S; Meng T; Liu J; Zhang X; Zhang J
    Medicine (Baltimore); 2015 Jan; 94(4):e445. PubMed ID: 25634181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
    Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
    Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Punicalagin protects H9c2 cardiomyocytes from doxorubicin-induced toxicity through activation of Nrf2/HO-1 signaling.
    Ye M; Zhang L; Yan Y; Lin H
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 31015369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.
    QuanJun Y; GenJin Y; LiLi W; YongLong H; Yan H; Jie L; JinLu H; Jin L; Run G; Cheng G
    PLoS One; 2017; 12(1):e0169567. PubMed ID: 28072830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
    Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
    Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
    Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
    Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resveratrol attenuates doxorubicin-induced cardiotoxicity in rats by up-regulation of vascular endothelial growth factor B.
    Tian W; Yang L; Liu Y; He J; Yang L; Zhang Q; Liu F; Li J; Liu J; Sumi S; Shen Y; Qi Z
    J Nutr Biochem; 2020 May; 79():108132. PubMed ID: 30857673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity.
    Gu J; Hu W; Zhang DD
    J Cell Mol Med; 2015 Oct; 19(10):2324-8. PubMed ID: 26177159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
    Yu X; Ruan Y; Shen T; Qiu Q; Yan M; Sun S; Dou L; Huang X; Wang Q; Zhang X; Man Y; Tang W; Jin Z; Li J
    Biomed Res Int; 2020; 2020():5107193. PubMed ID: 32190669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice.
    Bosman M; Krüger DN; Favere K; De Meyer GRY; Franssen C; Van Craenenbroeck EM; Guns PJ
    PLoS One; 2023; 18(11):e0294848. PubMed ID: 38015959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of dexrazoxane and amifostine against late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in vivo.
    Bjelogrlic SK; Lukic ST; Djuricic SM
    Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):228-38. PubMed ID: 23692343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
    Liesse K; Harris J; Chan M; Schmidt ML; Chiu B
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):417-425. PubMed ID: 29432315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity.
    Gu J; Hu W; Song ZP; Chen YG; Zhang DD; Wang CQ
    Int Immunopharmacol; 2016 Mar; 32():1-7. PubMed ID: 26774212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.